Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Boston Scientific Corporation (BSX) vs Blackstone Inc (BX) Price & Performance

Boston Scientific CorporationTrade
Blackstone IncTrade

Price performance (Past 24H)

Key statistics

Boston Scientific Corporation vs Blackstone Inc — how do they compare? Boston Scientific Corporation trades at $51.56 (market cap $74.19B), while Blackstone Inc trades at $145.56 (market cap $117.44B). The key difference: Blackstone Inc is the larger of the two by market cap, and Blackstone Inc pays a 3.55% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.

BSXBX
Market Cap
$74.19B$117.44B
Sector
HealthFinancials
52-Week High
$108.14$188.68
52-Week Low
$42.63$102.12
Enterprise Value
$86.27B
Dividend Yield
3.55%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Boston Scientific Corporation

Boston Scientific (BSX) trades at $51.27, up 1.6% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats in 2026, with Q2 EPS of $0.86 exceeding expectations. Revenue grew to $20.07B in 2025 with a 14.4% net margin, while analyst consensus shows 86% buy ratings with a $67.21 price target. Recent insider buying by the CEO and director signals confidence despite near-term guidance challenges.

BSX presents attractive valuation with 44% upside to consensus target, supported by strong fundamentals and institutional support. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with elevated RSI levels suggesting potential near-term consolidation. The long-term growth trajectory remains intact with 2026 revenue projected at $21B and 17.5% margins.

Blackstone Inc

Blackstone (BX) trades at $145.65, up 2.81% today, with strong technical momentum showing bullish moving averages and approaching resistance at $147. The company demonstrates robust fundamentals with revenue growth from $10.9B in 2024 to $12.4B in 2025 and net income margin of 25.85%. Recent acquisitions including the Aeroplan stake and HSBC's Australian loan portfolio highlight strategic expansion.

Outlook remains positive with analyst consensus at Buy (63%) and $144 price target, though RSI levels suggest potential overbought conditions. Key risks include private credit market strain and integration challenges from recent acquisitions. Earnings consistency with three consecutive beats supports the bullish case.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Boston Scientific Corporation

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Read more on BSX

About Blackstone Inc

Blackstone is one of the world's largest alternative asset managers with $940.8 billion in total asset under management, including $683.8 billion in fee-earning asset under management, at the end of June 2022.

Read more on BX